Niacin, or vitamin B3, is essential for turning food into energy and DNA repair, and is required by law to be added to enriched flour and cereal in the US since the 1930s - a fortification program credited with essentially eliminating pellagra, the once-common deficiency disease. At ordinary dietary intake, none of what follows applies to you. This article is about what happened when niacin, at doses 100 to 300 times the RDA, spent decades as a mainstream cholesterol treatment.
That story has three acts: a long run as a trusted lipid drug, a decisive rejection by two major clinical trials, and - as of 2024 - a genuinely new and unresolved question about whether niacin's own breakdown products might quietly work against the cardiovascular system they were meant to protect.
Act One: A Trusted Lipid Drug for Decades
Niacin's cholesterol effects are real and were never in dispute: high doses reliably raise HDL ("good" cholesterol) more effectively than almost any other agent, while lowering LDL, triglycerides, and lipoprotein(a). Given HDL's well-established inverse relationship with cardiovascular disease in observational data, adding niacin to statin therapy seemed like an obvious way to close the "residual risk" gap left over after statins alone.
Act Two: Two Trials That Ended the Practice
Act Three: A New, Unresolved 2024 Question
In February 2024, a Cleveland Clinic-led team published a metabolomics study in Nature Medicine identifying two terminal breakdown products of niacin metabolism - called 2PY and 4PY - that were associated with increased cardiovascular event risk in two separate patient cohorts.
The Core Finding
Patients in the top quartile of 2PY or 4PY blood levels had roughly double the three-year risk of major adverse cardiovascular events compared to the bottom quartile, after adjusting for traditional risk factors, across US and European validation cohorts.
A Plausible Biological Pathway
Follow-up genetic and mouse studies suggested 4PY specifically increases the pro-inflammatory vascular protein VCAM-1 in endothelial cells - giving the association a real, testable mechanism rather than just a statistical correlation.
Who Was Actually Studied
Both cohorts were patients already being evaluated for cardiac disease, roughly 60% of whom were on statins - a population where confounding by underlying disease severity is a genuine concern that observational metabolomics can't fully rule out.
Critical Commentary and a Correction
Nature Medicine published critical commentaries and an author response in September 2024, and issued an editorial correction to a claim about prior niacin research that had been stated too broadly in the original piece - a sign the finding is being actively debated, not quietly accepted.
This is a genuinely important, mechanistically plausible finding that deserves to be taken seriously and followed up in larger, ideally prospective studies - not dismissed. But it is not yet the kind of settled, randomized-trial-grade evidence that would justify a confident public health recommendation to reduce niacin fortification, and treating it that way overstates what one observational study, however well-designed, can establish. The honest position in mid-2026 is "actively being investigated," not "niacin is now known to be harmful."
The "No-Flush" Product Most People Reach for Instead
Given niacin's well-known flushing side effect - a harmless but uncomfortable warmth, redness, and itching caused by prostaglandin release - many people specifically seek out "no-flush" niacin, almost always sold as inositol hexanicotinate (IHN). This is where a separate, older controversy comes in.
The most rigorous head-to-head comparison available - a blinded, placebo-controlled trial comparing wax-matrix extended-release niacin, IHN, and placebo - found that IHN showed no evidence of bioavailability whatsoever in pharmacokinetic testing, and produced no significant improvement in cholesterol compared to placebo. The extended-release niacin group, by contrast, showed the expected significant lipid improvements. The reason IHN doesn't cause a flush may simply be that it isn't releasing meaningful amounts of active nicotinic acid into the bloodstream at all - not that it's delivering the same effect through a gentler route.
A Practical Quality Checklist
Before You Take Niacin for Any Purpose Beyond Basic Nutrition
Dosing
| Purpose | Typical Dose | Notes |
|---|---|---|
| General maintenance / RDA | 14-16mg/day (NE) | Easily met through diet for most adults; deficiency (pellagra) is now rare in fortified-food countries |
| Historical lipid management dose | 500 - 2,000mg/day, immediate or extended-release | The dose range tested in AIM-HIGH and HPS2-THRIVE - now a much harder case to justify given trial results |
| "No-flush" (inositol hexanicotinate) | Commonly 500 - 1,500mg/day | No demonstrated bioavailability as active niacin in the best available comparison trial |
Immediate-release niacin at drug-level doses commonly causes flushing, itching, and GI upset, and can worsen glycemic control, unmask diabetes, trigger gout, and cause elevated liver enzymes - extended-release and sustained-release formulations shift this risk profile toward more liver concern and less flushing. Any use above roughly 500mg/day for a therapeutic purpose should include medical supervision and periodic liver function and glucose monitoring. Niacin at ordinary dietary and standard multivitamin doses carries none of these concerns.
What It Stacks Well With
B-Complex (B1, B2, B6)
Niacin works alongside the other B-vitamins in overlapping energy-metabolism pathways at ordinary dietary and multivitamin doses.
Niacinamide (as NAD+ Precursor)
The non-flushing amide form is the more relevant one for the current NAD+/longevity conversation, separate from the cholesterol-dose controversy entirely.
Statins (Clinical Context)
The specific combination tested in AIM-HIGH and HPS2-THRIVE - now a much weaker case given both trials' results, worth revisiting with a prescriber if currently combined.
Statins + Myopathy Risk (Caution)
Combined niacin and statin use showed elevated rates of muscle-related adverse effects in trial data - a reason for monitoring, not automatic avoidance.
Diabetes Medications (Caution)
High-dose niacin can worsen glycemic control and interact with diabetes management - both AIM-HIGH and HPS2-THRIVE found excess new-onset diabetes.
Anticoagulants (Caution)
HPS2-THRIVE found an increased bleeding risk signal with high-dose niacin-laropiprant - relevant for anyone already on blood thinners.
Why niacin's HDL effect never translated into fewer heart attacks
See our framework for telling the difference between a surrogate marker improving and a treatment actually working.
- The AIM-HIGH Investigators (2011). Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. New England Journal of Medicine, 365, 2255-2267.
- HPS2-THRIVE Collaborative Group (2014). Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients. New England Journal of Medicine, 371, 203-212.
- Haynes, R. et al. (2019). Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the HPS2-THRIVE Trial. Journal of the American College of Cardiology.
- Ferrell, M. et al. (2024). A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk. Nature Medicine, 30(2), 424-434. Includes subsequent commentaries and author response (Sept. 2024).
- Sodi, R. (2024). Niacin and Risk of Cardiovascular Events: Deciphering the Paradox. Clinical Chemistry, 70(11), 1305-1307.
- Keenan, J.M. et al. Wax-matrix extended-release niacin vs inositol hexanicotinate: a comparison in persons with mild to moderate dyslipidemia. Journal of Clinical Lipidology.
- National Lipid Association (2014). Final Results of HPS2-THRIVE: Clinical Practice Recommendation.
Want the Complete Longevity Stack?
B3 is one piece of the puzzle. Get the full protocol - NMN, D3, Omega-3, dosing, stacking and a 30-day starter plan.
